All Articles

LEAP-005 Clinical Trial Yields Promising Efficacy and Safety Data for Patients with Gastric Cancer

Second-line or later nivolumab monotherapy yields no clear evidence of efficacy advantage for patients with advanced esophageal cancer.

CheckMate-648: Nivolumab with Ipilimumab or Chemotherapy Improves OS in Patients with Advanced Esophageal Squamous-Cell Carcinoma

Recently released positive findings from the LEAP-005 trial of lenvatinib plus pembrolizumab in the treatment of previously treated gastric cancer leads to cohort expansion.

DisTinGuish Part A Trial of DKN-01 plus Tislelizumab and CAPOX Results Indicate Early Activity in Patients with Advanced DKK1-High Gastroesophageal Adenocarcinoma

Results from the CheckMate-648 study demonstrate that nivolumab added to either ipilimumab or chemotherapy improves overall survival in patients with advanced esophageal squamous-cell carcinoma.

CheckMate-649: Survival Outcome Improved in Patients with Advanced Gastric/Esophageal Cancer Treated with Nivolumab Combined with Chemotherapy

DKN-01 plus tislelizumab and CAPOX combination demonstrates promising response rates and safety data in phase 2a study.

PET/CT Imaging in Prostate Cancer Patients

Nivolumab combined with chemotherapy had improved survival outcomes and an acceptable safety profile in patients with advanced gastric/esophageal cancer, according to CheckMate-649 study results.

Use of PYLARIFY® in Specific Patient Groups

By Neal D. Shore, MD

Interview with the Innovators

Video Library

Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.

MYLUNG Study Finds Majority of Patients with Untreated Metastatic NSCLC Tested for at Least One Biomarker

Early Integration of Interdisciplinary Supportive Care Leads to Improved Quality of Life for Patients with NSCLC

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests.

Therapeutic Patient Education Programs Found to Reduce Anxiety in Patients with Cancer

Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC.

KRAS G12C Mutations Have a Different Distribution Pattern in Asian Patients Compared with White Patients

Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program.